



CLOUD DIAGNOSTICS®

AWARD WINNING DISRUPTOR IN
VIRTUAL CARE AND DIGITAL MEDICINE

屡获大奖的线上护理和数字医疗领域的
颠覆者

CONFIDENTIALITY; NOTE REGARDING FORWARD-LOOKING STATEMENTS

This presentation (the “**Presentation**”) of Cloud DX Inc. (“**Cloud DX**” or the “**Corporation**”) and the material contained herein are strictly confidential and are not to be disclosed to the public, reproduced or distributed to any other person or published, in whole or part, for any purpose whatsoever. This Presentation is for information purposes of the recipient only and shall not constitute an offer to sell, or a solicitation or an offer to buy, any securities of the Corporation in any jurisdiction where such offer, solicitation or sale would be unlawful. The information contained herein is subject to change without notice and is based on publicly available information, internally developed data and other sources. Where any opinion or belief is expressed in this Presentation, it is based on the assumptions and limitations mentioned herein and is an expression of present opinion or belief only. This Presentation should not be construed as legal, financial or tax advice to any individual, as each individual’s circumstances are different. The recipient of this Presentation should consult with its own professional advisors regarding its particular circumstances. Unless defined herein, all capitalized words shall have the meanings ascribed to them elsewhere in the Presentation.

This Presentation contains certain forward-looking statements and forward-looking information (collectively referred to herein as “**forward-looking statements**”) within the meaning of applicable securities laws. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as “anticipate”, “achieve”, “could”, “believe”, “plan”, “intend”, “objective”, “continuous”, “ongoing”, “estimate”, “outlook”, “expect”, “may”, “will”, “project”, “should” or similar words, including negatives thereof, suggesting future outcomes. Forward-looking statements in this Presentation may include, among other things, statements about: our business strategy and performance expectations, including sales growth expectations; general expectations regarding the growth of, trends in and projected value of the remote patient monitoring (“**RPM**”) market; our revenue and revenue growth models; expected opportunities for market share penetration and our expected sales pipeline; the expected long term impacts of COVID-19 on demand in the RPM market; the availability of government funding, grants and private insurance coverage to subsidize products and services in the RPM industry, including our products and services; our plans for future products and services, and for enhancements to our existing products and services; our future intellectual property; expectations regarding key areas of growth in the industry; our future growth strategy and growth rate; expectations regarding future revenue, revenue growth, profit and loss, cost of goods sold, gross margin, selling, general and administrative expenses, other income and expenses and EBITDA, including our expectation of becoming EBITDA-positive in 2022; our competitive market and the expected revenue growth, future revenue, EBITDA and margins for certain of our competitors; the expected *pro forma* capitalization of the Corporation;

the nature, timing and price of the Offering; the expected business combination transaction with a listed Canadian reporting issuer; the expected future board of directors assuming completion of the business combination; and the use of proceeds of the offering. Such statements and information are based on numerous assumptions regarding present and future business strategies and the environment in which the Corporation will operate in the future, including: the demand for our products and services, including from existing customers; our ability to upgrade technology and develop technological improvements; anticipated costs and our ability to achieve goals; our ability to attract and retain experienced personnel and executive leadership; our ability to anticipate the future needs of our customers; our ability to maintain supplier and customer relationships; sales opportunities available to us; our ability to increase revenue by increasing our sales and marketing expenses; the creditworthiness of our contract counterparties; that our products and services will remain competitive by outperforming standard devices of our competitors; our ability to obtain all necessary regulatory approvals and patent and intellectual property protections for our products and services; the continued integration of our products and services with leading third-party devices, operating systems, apps, web browsers and API integrations; the continued availability of government funding, grants and private insurance coverage to subsidize products and services in the RPM industry, including our products and services; our ability to access future capital investment; the size of the Offering; the completion of the Offering; and the use of proceeds therefrom; and to the extent needed, that additional financing is available. Although we believe that the assumptions underlying these statements are reasonable, they may prove to be incorrect. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements.

Forward-looking statements in this Presentation are subject to known and unknown risks, uncertainties and other important factors that may cause the actual results to be materially different from those expressed or implied by such forward-looking statements, including but not limited to: the fact that Cloud DX is an early stage company with a short operating history and may not actually achieve its plans, projections, or expectations; the fact that Cloud DX is not expected to generate profit in the foreseeable future and will continue to incur significant operating losses while it continues further research and development, pursues regulatory approvals and commercialization of its products and further implements its business plans; the business model and certain key development stage products are unproven and may never be successful or generate any significant revenues or profits; our ability to manage our operating expenses, which may adversely affect our financial condition; research to date of certain products of Cloud DX is in the early stages with limited clinical data and no assurance can be given that

the preliminary data will ultimately be validated or lead to successful commercial products; our ability to remain competitive as other better financed competitors develop and release competitive products; changes in laws; regulatory uncertainties; a substantial delay or denial in the approval by the FDA or other negative regulatory processes or limitations on Cloud DX’s abilities to test or market its products consistent with their intended uses, could result in a material adverse effect on Cloud DX’s business plans, results of operations, and financial conditions; our dependence on our intellectual property rights; our ability to successfully maintain and enforce our intellectual property rights and defend third-party claims of infringement of their intellectual property rights; the impact of intellectual property litigation that could materially and adversely affect our business; our failure to develop new and innovative products; our reliance on novel technologies which presently include investments in innovative medical technologies; the impact of technological changes on our products and industry; our failure to develop technological upgrades and new technologies; the impact of product liability claims that could materially and adversely affect our business; our ability to attract, retain and motivate qualified personnel and key employees; failure of counter-parties to perform their contractual obligations; business, economic and market conditions; demand and pricing for our products; whether Cloud DX can continue as a going concern will be dependent on raising additional capital and ultimately reaching profitability; our requirement to raise additional financing to fund operating losses and among other things, continue product development and testing, pursue regulatory approvals, develop sufficient marketing and distribution networks, create a sufficient network of trained doctors capable of using our products, purchase fixed assets and pay salaries and other operating expenses and expand manufacturing capabilities and create inventory; the broad discretion of the board of directors of Cloud DX to apply proceeds from financings; the return of capital and the realization of gains, if any, from an investment in Cloud DX will occur only upon sale, licensing or other significant liquidity transaction, or the Corporation obtaining meaningful profitability; and there presently being no market, public or private, for the securities of Cloud DX.

Except as required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. Neither we nor any of our representatives make any representation or warranty, express or implied, as to the accuracy, sufficiency or completeness of the information in this Presentation. Neither we nor any of our representatives shall have any liability whatsoever, under contract, tort, trust or otherwise, to you or any person resulting from the use of the information in this Presentation by you or any of your representatives or for omissions from the information in this Presentation.

Unless otherwise noted, all figures are in US Dollars.除非另有说明，所有数字均为美元。

FUNDING & COMPANY

Cloud DX is on a mission to make healthcare better for everyone. Cloud DX的使命是让每个人都能更好地享受医疗保健。

We do that by creating and commercializing new medical devices, mobile apps and clinical services to improve the delivery of care outside the four walls of a clinic or hospital.我们通过创造和商业化新的医疗设备、移动应用程序和临床服务来改善诊所或医院外的护理服务。

Cloud DX is a disruptor in the new and rapidly growing fields of virtual care, telehealth and digital medicine. / Cloud DX是虚拟护理、远程医疗和数字医疗等新的和快速增长领域的颠覆者。

Equity Raised 股权募资	\$29.0 million CAD / 2900万加元
Non-Dilutive Funding 非股权摊薄募资*	\$4.5 million CAD / 450万加元

Total Funds to Cloud DX 总募资额 \$33.5 million CAD / 3350万加元

Grants to Partners 给合作伙伴的补助金**	\$11.0 million CAD / 1100万加元
--------------------------------	------------------------------

* Includes 'other income' directed to Cloud DX for research & commercialization 包括用于研究和商业化给予Cloud DX的"其他收入"。
** Funding to 3rd parties for R&D directly benefiting Cloud DX, not counted as income. ** 向第三方提供资金用于研发，直接使Cloud DX受益，不计入收入。

Founded 创立时间	2014
Certifications 认证	ISO 13485 Health Canada MDL Health Canada MDEL FDA Registration FDA 510(k) FDA MDDS



Offices 办公室	Kitchener, ON (Tech Centre) 安大略省吉奇纳（技术中心） Brooklyn, NY (US HQ) 纽约布鲁克林（美国总部）
--------------------	--------------------------------------------------------------------------------

Auditors 审计机构	
Legal 法律	

EXECUTIVE TEAM 高管团队

Cloud DX leadership combines extensive startup, scale up, public company and clinical experience. / Cloud DX领导团队拥有丰富的创业、扩大规模、上市公司和临床经验。



Robert Kaul

Founder & CEO
创始人兼首席执行官

A serial entrepreneur with 3 successful exits; former CEO of Biosign Technologies Inc. (TSXV:BIO) 一个有三次成功退出经历的连续创业者；曾任Biosign Technologies Inc. (TSXV:BIO) 的首席执行官。



Anthony Kaul

Co-founder & COO
联合创始人兼首席运营官

Founder & former CEO of HigherBracket Online Media; HR and supply chain expert / HigherBracket Online Media的创始人和前CEO；人力资源和供应链专家



Dr Sonny Kohli

Co-founder & CMO
联合创始人兼首席营销官

Practicing ICU physician, Halton Healthcare; former Canadian Space Agency astronaut candidate, public speaker / Halton Healthcare的ICU执业医师；前加拿大航天局宇航员候选人，公共演讲者



Stephanie Bird

CA, CPA 注册会计师
CFO 首席财务官

Multidiscipline executive with deep experience leading finance, operations and risk management teams具有领导财务、运营和风险管理团队的深厚经验的多面手高管

BOARD OF DIRECTORS 董事会



Robert Kaul ★

Former CEO & director of Biosign Technologies Inc. (TSXV:BIO)
曾任Biosign Technologies Inc. (TSXV:BIO)的首席执行官兼董事



Dr Sonny Kohli

Former director of Biosign; currently enrolled at ICD–Rotman Directors Education Program 曾任Biosign的董事，目前就读于ICD–Rotman董事教育课程的学生



Michele Middlemore ♀

Former Cloud DX interim-CFO, Chartered Accountant; former VP of Hospice Toronto 曾任Cloud DX临时首席执行官，注册会计师，曾任Hospice Toronto副总裁



Brad Miller ☆ ♀

Founder & CEO of Advantec Global; former director of ParkIt Enterprise Inc. (TSXV:PKT) / Advantec Global的创始人兼首席执行官，曾任ParkIt Enterprise Inc. (TSXV:PKT)的董事



Dr Constantine Zachos ♀

Practicing physician; currently director at Exerkine Corporation, Toronto, ON 执业医师；现任安大略省多伦多市Exerkine Corporation董事。



William Charnetski ♀

Former Ontario Health Innovation Strategist; currently EVP at PointClickCare; former director at Waterfront Toronto 曾任Ontario Health Innovation的策略师和Waterfront Toronto的董事，现任PointClickCare的执行副总裁

★ Chairman of the Board 董事会主席 ☆ Lead Independent Director 首席独立董事 ♀ Audit Committee Chair 审计委员会主席 ♀ Audit Committee Member 审计委员会会员 ♀ Compensation Committee Chair 薪酬委员会主席 ♀ Compensation Committee Member 薪酬委员会会员

RECOGNITION OF EXCELLENCE

优秀表彰



For “Exponential technological progress in the field of consumer-focused medical technologies with the greatest potential for expanding access to healthcare when deployed at scale”
获奖理由: “在以消费者为中心的医疗技术领域取得了指数级的技术进步，在大规模部署时具有扩大医疗服务的最大潜力”



2018 WORLD CHANGING IDEAS FINALIST



THE VIRTUAL CARE REVOLUTION 线上医疗革命

Remote patient monitoring (RPM) and telemedicine enable early interventions by doctors, reduced hospital admissions, improved patient survivability, and savings up to billions per year¹ 远程病人监测（RPM）和远程医疗使医生能够进行早期干预，减少入院人数，提高病人的存活率，每年可节省数十亿美元¹

“THE PANDEMIC HAS USHERED IN THE NEXT TRILLION-DOLLAR BUSINESS 这场疫情开辟了下一个万亿美元的业务”



December 5, 2020
/ 2020年12月5日

“POST COVID, THERE’S NO GOING BACK. THE WRITING IS ON THE WALL: PEOPLE LIKE VIRTUAL CARE. HOSPITALS LIKE IT. AND INCREASINGLY, INVESTORS ARE LIKING IT TOO 在新冠疫情之后，已经没有回头路了。可以预见：人们喜欢线上护理，医院也喜欢。而且，越来越多的投资者也喜欢它”

– Christopher McFadden,
Managing Director of Healthcare at KKR & Co. /
Healthcare at KKR & Co.董事总经理²

“>50% OF CANADIANS’ MOST RECENT HEALTH ENCOUNTERS WERE VIRTUAL.” “50%以上的加拿大人最近的健康访问是线上的”。”³

1. www.cihi.ca

2. Healthcare Finance, Dec 14, 2020 / 2020年12月14日

3. CMAJ, July 2020 / 2020年7月

TOTAL AVAILABLE MARKET 总市场

5+
Million

People in Canada over 35 who suffer from COPD, CHF or their precursors
加拿大有**500**万以上**35**岁以上的人患有**COPD**、**CHF**或其前兆^{1,2}

COPD - Chronic Obstructive Pulmonary Disease 慢性阻塞性肺部疾病
CHF - Congestive Heart Failure 充血性心力衰竭

1. <https://health-infobase.canada.ca/datalab/copd-blog.html>
2. <https://www.canada.ca/en/public-health/services/publications/diseases-conditions/heart-disease-canada-fact-sheet.html>

50+
Million

Americans who qualify for reimbursed RPM 符合报销**RPM**条件的美国人超过**5000**万³

38.2%
Projected

Annual growth of the RPM market between 2020 and 2025 / 2020年至**2025**年间，**RPM**市场的年增长率预计为**38.2%**⁴

3. <https://www.cms.gov/medicare/>
4. Remote Patient Monitoring (RPM) Market by Product & End User - Global Forecast to 2025 - Markets And Markets, September 15, 2020. 按产品和终端用户划分的远程患者监测 (RPM) 市场-2025年全球预测-Markets And Markets, 2020年9月15日。

\$117
Billion

Projected value of the RPM market by 2025 到**2025**年**RPM**市场预计价值**\$1170**亿⁴

OUR PROVEN VIRTUAL CARE PLATFORM

我们经过验证的线上护理平台

Cloud DX goes beyond standard telemedicine offerings through unique data collection hardware, software & key differentiators / Cloud DX通过独特的数据收集硬件、软件和关键的差异化手段，超越了标准的远程医疗产品。

VCaaS

“Virtual Care as a Service 线上护理即服务”

- Remote patient monitoring 远程患者监测
- Clinician dashboards 临床医师提醒板
- Telemedicine visits 远程访问
- Text messaging 文本信息
- Symptom tracking 症状跟踪
- Wound care 伤口护理
- Patient engagement tools 患者参与工具



Connected Health Kit and Mobile App 联网健康工具包和移动应用程序



Online Clinician Portal 在线临床医生门户网站

Key Differentiators 关键的差异化因素:

- Sales to hospitals across Canada 向加拿大全国的医院销售
- Beat out top competitors (e.g., GE, Philips, Telus) 击败顶级竞争对手 (例如, GE、Philips、Telus)
- Devices are easier to use 设备更容易使用
- Unique cardiac data gathered 收集到的独特的心脏数据
- More accurate vital signs 更准确的生命体征¹
- Unified user experience 统一的用户体验
- >90% patient compliance 患者依从性超过90%²
- 100% patient satisfaction 患者满意度达到100%³
- Excellent clinician approval 优秀的临床医生认可⁴

1. “A Comparison and Calibration of a Wrist-Worn Blood Pressure Monitor for Patient Management”, JMIR, April 2018
“用于患者管理的腕戴式血压计的比较和校准”, JMR, 2018年4月

2. “Technology-Enabled Self-Management of Chronic Obstructive Pulmonary Disease”, JMIR, July 2020.
“技术驱动的慢性阻塞性肺病的自我管理”, JMR, 2020年7月

3. 100% patient satisfaction scores in multiple studies: UAMS, MSH, UNB. 在多项研究中, 患者满意度为100%: UAMS, MSH, UNB。 4. Physician net promoter score of 82, “Breathe Right at Home” project, 2018. / 2018年, “居家呼吸”项目, 医生净推动者评分为82分。

DIVERSIFIED REVENUE MODEL 多元化营收模式

Cloud DX earns revenue by delivering a complete Virtual Care solution. / Cloud DX通过提供完整的线上护理解决方案来赚取收入。



Software & Services 软件和服务

- Connectivity 连通
- Software applications 软件应用
- Client support 客户支持
- Patient compliance & logistics 患者依从和后勤



Hardware 硬件

- Cloud DX medical devices we create & sell 我们创造和销售Cloud DX医疗设备
- RPM kits for many reimbursed use cases 用于许多报销用例的RPM工具包
- Curated selection of 3rd party devices 精心挑选的第三方设备



Customizations 定制

- Customized surveys 定制的调查
- Content & features 内容和特点
- Integration of new hardware devices to the platform 将新的硬件设备整合到平台上



Licensing 许可

- Our trademarks 我们的商标
- White labeling our software 白色标签我们的软件
- Designing bespoke programs 设计定制的方案

DIFFERENTIATORS 差异化

Proprietary Data 专有数据



Cloud DX's unique devices gather data on cardiac functions, movement and even battery levels that no other RPM devices collect. / Cloud DX的独特设备收集关于心脏功能、运动甚至电池水平的数据，这是其他RPM设备无法收集的。

Service Excellence 卓越服务



Cloud DX customer service, for patients and clinicians, is extraordinary – proven by multiple 100% satisfaction scores in 3rd party studies.对患者和临床医生来说，Cloud DX的客户服务是非常优秀的 – 第三方研究中多个100%的满意度分数证明了这一点。

End-to-end UX design 端到端UX设计



Only Cloud DX controls the entire RPM user experience including unique medical devices, mobile apps, and clinical dashboards.只有Cloud DX控制整个RPM用户体验，包括独特的医疗设备、移动应用和临床仪表盘。

Created by, for & with Doctors 医生参与、使用产品，与医生合作



We have deep relationships with the medical community as customers and investors. Cloud DX raised ~\$15M in capital from Physicians.我们与作为客户和投资者的医疗界有着深厚的关系。Cloud DX从医生那里筹集了约\$1500万的资金。

Nimbleness 灵活



Our team specializes in creating new features in record time, allowing our clients to customize their deployment faster.我们的团队擅长在创纪录的时间内创建新功能，使我们的客户能够更快地定制他们的产品。

Genuine Innovators 真正的创新者



Cloud DX is developing three entirely new products. We've received over a dozen Innovation Awards including Canada's only XPRIZE. / Cloud DX正在开发三种全新的产品。我们已经获得了十多个创新奖，包括加拿大唯一的XPRIZE。

CUSTOMERS 客户



TRACTION 牵引力: 2019-2022

Virtual care shifted into high gear in 2020 due to COVID-19

由于发生新冠疫情，线上护理在2020年转入高速发展。


- **Cloud DX SaaS contracts** typically run for 12 to 36 months and are open-ended on patient numbers / Cloud DX的SaaS合同通常为12至36个月，对患者数量没有限制。
- **As patient enrollment** increases within a contract, SaaS revenue increases over time 随着合同内患者注册人数的增加，SaaS收入也会随着时间的推移而增加。
- **Revenue from licensing** agreements and government contracts are in addition to SaaS-type contracts 来自许可协议和政府合同的收入是在SaaS类型合同之外的收入
- **2020 revenue** from ongoing contracts increased by >150% over 2019 and we project a >300% increase in 2021 / 2020年来自正在进行的合同的收入比2019年增加了150%以上，我们预计2021年将增加300%以上。
- **Contracts executed** in 2020 account for an estimated **\$4.0 million** in SaaS revenue projected for 2021-2022 / 2020年执行的合同估计占到预计2021-2022年的SaaS收入为**\$400万**。

**IN 2020,
PATIENTS
ENROLLED
GREW BY 700%**

在2020年，注册的患者增长了700%。




MILESTONES TO DATE 截止目前实现的里程碑

Cloud DX has accomplished many critical milestones since our founding in 2014. These are some examples 自2014年成立以来, Cloud DX已经完成了许多重要的里程碑。 以下是一些例子:



GO TO MARKET 推向市场

Cloud DX is pursuing three main go-to-market channels in both Canada and the USA
在加拿大和美国，Cloud DX正在寻求三个主要的市场推广渠道。：

	B2B	B2B2B	B2G
Client 客户	Hospitals Clinical Practices 医院临床实践	Commercial partners Value added resellers 商业合作伙伴，增值经销商	Provincial Health Authorities Government projects 省级卫生机构，政府项目
Payer 支付方	Insurance (Medicare, Private) 保险（医保、私人）	Commercial end user Insurance (Medicare, Private) 商业终端用户保险（医保、私人）	Government contract 政府合同
Examples 示例			
Marketing 营销	Refferal from existing clients Targeted marketing Direct –email, mail, phone 现有客户推荐、定向市场营销，直接通过电邮、快递和电话方式	Co-marketing campaigns Marketing support 合作营销活动，营销支持	Request for Proposals (RFPs) Relationship marketing Competitive project awards 征求建议书（RFP），关系营销，竞争性项目奖励
Pricing 定价	Subscription model: per patient per month 订阅模式：每位患者每月 Hardware can be purchased separately or amortized into subscription payments Fully reimbursed in the United States under Medicare CPT Codes 99453, 99454 硬件可以单独购买，也可以摊入订阅费用，在美国可根据医疗保险CPT代码99453、99454完全报销。		

INNOVATIVE TECHNOLOGY PIPELINE 创新的技术管线

New products in development, validation and commercialization
正在开发、验证和商业化的新产品




PulseWave2

Wrist cuff spot monitor 腕帶定点监测仪

Superior BP, heart rate & respiration monitor gathers unique clinical-grade data we can monetize 卓越的血压、心率和呼吸监测仪收集了独特的临床级数据，我们可以将其货币化。

Patented
获得专利




VITALITI™

Wearable monitor 可穿戴监测仪

Unique low cost wearable earns reimbursement for both cardiac telemetry and continuous BP 独特的低成本可穿戴设备为心脏遥测和连续血压赢得了报销的机会

Patents pending
正在申请专利



QUALCOMM
TRICORDER XPRIZE
WINNING APP

AcuScreen CA™

Cough Analysis app 咳嗽分析应用程序

Smartphone app that screens for the most deadly respiratory diseases in the developing world incl. TB 筛查发展中国家最致命的呼吸道疾病（包括肺结核）的智能手机应用程序。

Patented
获得专利

REVENUE GROWTH 营收增长

As the post COVID virtual care & digital medicine industry expands exponentially, our revenues are expected to grow in 4 key areas 随着疫情后线上护理和数字医疗行业的飞速发展，我们的收入预计将在四个关键领域增长：

1. Within Contracts 现有合同

Current customers are already ordering more kits & services 目前的客户已经在订购更多的工具包和服务



as examples - many contracts are expected to increase orders 作为例子--许多合同预计将增加订单

2. New Contracts 新合同

We're increasing our sales & marketing spend by up to 500% in 2021 / 2021年我们正在将我们的销售和营销支出增加500%。



3. New Products 新产品

As each new product comes to market, ARR increases 随着每个新产品的上市，ARR会增加



4. New Markets 新市场

Outside of N.A. we have prospects in Europe, the Middle East & Australia 在北美之外，我们在欧洲、中东和澳大利亚都有前景。



FINANCIAL SNAPSHOT 财务数据

Insiders* (Officers and Directors) who own ~32% of issued shares, have agreed to restrict any sale of shares owned on or before the closing of the Qualifying Transaction for a period of 12 months. Please see the Filing Statement on SEDAR for more details on Insider sale restrictions. 拥有约32%已发行股份的内部人士*（高管和董事）已同意在12个月内限制出售在合格交易结束时或之前拥有的任何股份。请参阅SEDAR上的备案声明，以了解关于内部人出售限制的更多细节。

	Post QT 合格交易后
Issued and Outstanding 已发行股份	72,094,388
Fully Diluted 完全摊薄后股数	84,682,700
Float 流通股	48,752,730
Insider % 内部人士持股比例	32.3%

*as defined by the TSXV 按照多交所创业板规定



WHY INVEST IN CLOUD DX? 为何投资CLOUD DX?

- **Digital and virtual health care are the world's fastest growing sectors:** virtual health care alone projected CAGR of 38% to 2026.数字和线上医疗是世界上增长最快的领域: 仅线上医疗预计到2026年的年复合增长率为38%。¹
- **At over \$250 billion annually** virtual health care is a large and attractive market for investment.每年超过\$2500亿的线上医疗是一个庞大而有吸引力的投资市场。²
- Remote patient monitoring (RPM), a subset of virtual care, is expected to grow to **\$117 billion annually** by 2025.远程病人监测(RPM)是线上护理的一个部分, 预计到2025年将增长到每年\$1170亿。³
- **Cloud DX is an award-winning technology provider: XPRIZE Bold Epic Innovator Award; 2021 Edison Award Winner; many more awards / Cloud DX是一个屡获殊荣的技术提供者: XPRIZE大胆史诗创新奖、2021年爱迪生奖以及其他奖项**
- **High quality, recurring revenue:** ongoing contract receipts show significant year over year growth.高质量、经常性的收入: 持续的合同收入显示出明显的同比增长。
- **Traction: number of patients enrolled in 2020 by Cloud DX increased 700%. 牵引力: 2020年Cloud DX注册的患者数量增加了700%。**
- **Financial strength:** multi year contracts in the public and private sectors provide strong cash flow.财务实力: 公共和私营部门的多年合同提供了强大的现金流。
- **Patented, inhouse designed and manufactured tools for remote patient monitoring.** 公司内部设计和制造的远程患者监测工具已获得专利
- **Experienced management team & board:** provides Cloud DX with broad experience in med tech & public company domain.经验丰富的管理团队和董事会: 为Cloud DX提供在医疗技术和上市公司领域的广泛经验。
- **Cloud DX is a revenue generating blue sky opportunity.** Cloud DX是一个创造收入的巨大机会。

1. Remote Patient Monitoring (RPM) Market by Product & End User - Global Forecast to 2025 - Markets And Markets, September 15, 2020. 按产品和终端用户划分的远程患者监测 (RPM) 市场-2025年全球预测--Markets And Markets, 2020年9月15日。

2. McKinsey report June 2020. 麦肯锡2020年6月的报告。

3. Remote Patient Monitoring (RPM) Market by Product & End User - Global Forecast to 2025 - Markets And Markets, September 15, 2020. 按产品和终端用户划分的远程患者监测 (RPM) 市场-2025年全球预测--Markets And Markets, 2020年9月15日。



Financial Information: Certain financial information included in this document is unaudited. There is a material risk that the audited financial results would differ significantly from unaudited financial information presented herein.

Certain information in this Presentation contain references to non-IFRS measures, such as EBITDA, that do not have standardized meaning under IFRS as prescribed by the International Accounting Standard Board and are therefore unlikely to be comparable to similar measures presented by other companies. These measures are provided as additional information to complement IFRS measures by providing further understanding of the Corporation's operations from management's perspective. Non-IFRS measures should not be considered in isolation or as a substitute for analysis of financial information under IFRS.

To the extent any forward looking information in this Presentation constitutes future-oriented financial information and financial outlook information (collectively, **"FOFI"**) within the meaning of applicable Canadian securities laws, such information is being provided as of the date of this Presentation and is provided for the purpose of providing information: (i) about management's current expectations and plans relating to the future; and (ii) to demonstrate the potential benefits of the Corporation's business plans and strategies, and the reader is cautioned that this information may not be appropriate for any other purpose and should not place undue reliance on such FOFI. As with forward-looking information generally, FOFI are, without limitation, based on the assumptions and subject to certain risks, including without limitation, those set out above under the heading "Note Regarding Forward-Looking Statements". The Corporation's actual financial position and results of operations may differ materially from management's current expectations and, as a result, the Corporation's future revenues, revenue growth, margins, and EBITDA may differ materially from future-oriented financial information provided in this Presentation. Such information is presented for illustrative purposes only and may not be an indication of the Corporation's actual financial position or results of operations.

Third Party Information: This Presentation also contains or references certain market, industry and peer group data which is based upon information from independent industry publications, market research, analyst reports and surveys and other publicly available sources. Although the Corporation believes these publications and reports to be reliable, it has not independently verified any of the data or other statistical information contained therein, nor has it ascertained or validated the underlying economic or other assumptions relied thereon by these sources and cannot, and does not, provide any representation or assurance as to the accuracy or completeness of the information or data, or the appropriateness of the information or data for any particular analytical purpose, and accordingly, disclaims any liability in relation to such information and data. The Corporation has no intention and undertakes no obligation to update or revise any such information or data, whether as a result of new information, future events or otherwise, except as required by law.

Trademarks and Trade Names: The Corporation owns or has rights to various trademarks, service marks and trade names that it uses in connection with the operation of its business. This Presentation also contains trademarks, service marks and trade names of third parties, which

are the property of their respective owners. The Corporation's use or display of third parties' trademarks, service marks, trade names or products in this Presentation is not intended to, and does not imply, a relationship to Cloud DX or an endorsement or sponsorship by or of Cloud DX. Solely for convenience, the trademarks, service marks, and trade names referred to in this Presentation may appear without the ®, ™ or SM symbols, but such references are not intended to indicate, in any way, that the Corporation or the applicable third party that is the owner of any such trademark, service mark or trade name, as applicable, will not assert, to the fullest extent under applicable law, its right or the right of the applicable licensor to the applicable trademark, service mark or trade name.

CAUTIONARY NOTE TO RECIPIENTS IN THE UNITED STATES: THIS PRESENTATION AND THE MATERIAL CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL OR A SOLICITATION OF AN OFFER TO BUY ANY SECURITIES IN CLOUD DX INC. OR 12632926 CANADA LTD. SUCH AN OFFER AND SOLICITATION MAY ONLY BE MADE PURSUANT TO A PRIVATE SUBSCRIPTION AGREEMENT AND OTHER APPLICABLE DOCUMENTS (THE **"OPERATIVE DOCUMENTS"**), WHICH SHOULD BE READ IN THEIR ENTIRETY. THE STATEMENTS IN THIS PRESENTATION ARE NOT INTENDED TO BE COMPLETE OR FINAL AND ARE QUALIFIED IN THEIR ENTIRETY BY REFERENCE TO THE OPERATIVE DOCUMENTS. IN THE EVENT THAT THE DESCRIPTIONS OR THE TERMS DESCRIBED HEREIN ARE INCONSISTENT WITH OR CONTRARY TO THE DESCRIPTIONS IN OR THE TERMS OF THE OPERATIVE DOCUMENTS, THE OPERATIVE DOCUMENTS SHALL GOVERN. THEREFORE ANY RECIPIENT HEREOF SHOULD READ THE OPERATIVE DOCUMENTS AND SHOULD CONDUCT ITS OWN INDEPENDENT ANALYSIS OF THE DATA REFERRED TO HEREIN.

THE SECURITIES DESCRIBED HEREIN HAVE NOT AND WILL NOT BE REGISTERED UNDER THE SECURITIES ACT OF 1933 (THE **"SECURITIES ACT"**) OR ANY US STATE SECURITIES LAWS OR UNDER THE SECURITIES LAWS OF CANADA OR ANY OTHER JURISDICTION. EACH PURCHASER IN THE UNITED STATES MUST BE A "QUALIFIED INSTITUTIONAL BUYER" AS DEFINED BY RULE 144A UNDER THE SECURITIES ACT OR AN "ACCREDITED INVESTOR" AS DEFINED BY REGULATION D UNDER THE SECURITIES ACT.

Canadian Investor Notice; Statutory Rights of Action: In certain circumstances, purchasers resident in certain provinces of Canada, are provided with a remedy of rescission or damages, or both, in addition to any other right they may have at law, where an offering memorandum (such as this Presentation) and any amendment to it contains a misrepresentation. Where used herein, "misrepresentation" means an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made. These remedies, or notice with respect to these remedies, must be exercised or delivered, as the case may be, by the purchaser within the time limits prescribed by applicable securities legislation. The following summary is subject to the express provisions of the applicable securities laws, regulations and rules, and reference is made thereto for the complete text of such provisions. Such provisions may contain limitations and statutory defences not described here on which the Corporation and other applicable parties may rely. Purchasers should refer to the applicable provisions of the securities legislation of their provinces for the particulars of these rights or consult with a legal adviser.


The following is a summary of rights of rescission or damages, or both, available to most purchasers resident in the province of Ontario, New Brunswick, Nova Scotia and Saskatchewan. If there is a misrepresentation herein and you are a purchaser under securities legislation in Ontario, New Brunswick, Nova Scotia or Saskatchewan you have, without regard to whether you relied upon the misrepresentation, a statutory right of action for damages, or while still the owner of the securities, for rescission against the Corporation. This statutory right of action is subject to the following: (a) if you elect to exercise the right of action for rescission, you will have no right of action for damages against the Corporation; (b) except with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission after 180 days from the date of the transaction that gave rise to the cause of action; (c) no action shall be commenced to enforce a right of action for damages after the earlier of (i) 180 days (with respect to purchasers resident in Ontario) or one year (with respect to purchasers resident in Saskatchewan and New Brunswick) after you first had knowledge of the facts giving rise to the cause of action and (ii) three years (with respect to purchasers resident in Ontario) or six years (with respect to purchasers resident in Saskatchewan and New Brunswick) after the date of the transaction that gave rise to the cause of action; (d) with respect to purchasers resident in Nova Scotia, no action shall be commenced to enforce a right of action for rescission or damages after 120 days from the date on which payment for the securities was made by you; (e) the Corporation will not be liable if it proves that you purchased the securities with knowledge of the misrepresentation; (f) in the case of an action for damages, the Corporation will not be liable for all or any portion of the damages that it proves do not represent the depreciation in value of the securities as a result of the misrepresentations; and (g) in no case will the amount recoverable in such action exceed the price at which securities were sold to you. The foregoing is a summary only and is subject to the express provisions of the Securities Act (Ontario), the Securities Act (New Brunswick), the Securities Act (Nova Scotia) and the Securities Act (Saskatchewan), and the rules, regulations and other instruments thereunder, and reference is made to the complete text of such provisions contained therein. Such provisions may contain limitations and statutory defences on which the Corporation may rely.

In Manitoba, the Securities Act (Manitoba), in Newfoundland and Labrador, the Securities Act (Newfoundland and Labrador), in Prince Edward Island, the Securities Act (PEI), in Yukon, the Securities Act (Yukon), in Nunavut, the Securities Act (Nunavut) and in the Northwest Territories, the Securities Act (Northwest Territories) provide a statutory right of action for damages or rescission to purchasers resident in Manitoba, Newfoundland, PEI, Yukon, Nunavut, and Northwest Territories respectively, in circumstances where this Presentation or an amendment hereto contains a misrepresentation, which rights are similar, but not identical, to the rights available to Ontario purchasers.

The statutory right of action described above is in addition to and without derogation from any other right or remedy at law.




Contact Investor Relations
投资者关系联系方式
investor.relations@clouddx.com



TECHNOLOGY CENTRE

技术中心
100 - 72 Victoria St South
Kitchener, ON N2G 4Y9
888-543-0944
info@clouddx.com



US HEADQUARTERS

美国总部
20 Jay Street, Unit 834
Brooklyn, New York 11201
888-543-0944
info@clouddx.com